Snapshot img

Travel Vaccines Market Size 2025-2029

The travel vaccines market size is forecast to increase by USD 7.05 billion, at a CAGR of 10.7% between 2024 and 2029.

Major Market Trends & Insights

North America dominated the market and accounted for a 46% growth during the forecast period.
By the Disease Type - Influenza segment was valued at USD 3.44 billion in 2023
By the End-user - Adult vaccines segment accounted for the largest market revenue share in 2023

Market Size & Forecast

Market Opportunities: USD 112.15 billion
Market Future Opportunities: USD 7.05 billion 
CAGR : 10.7%
North America: Largest market in 2023

Market Summary

The market is a significant sector within the healthcare industry, demonstrating continuous growth and evolution. According to various market research, the demand for travel vaccines is on the rise, with an estimated 250 million international travelers in 2020. This number is projected to reach 380 million by 2027, representing a substantial increase. Travelers' changing demographics and increased global connectivity contribute to this market expansion. For instance, an aging population and the rise of adventure tourism are key factors driving the need for diverse travel vaccines. Moreover, the market is witnessing the emergence of new vaccine types, such as combination vaccines, which offer enhanced protection against multiple diseases.
The market's dynamism is further fueled by advancements in technology, enabling the development of more effective and convenient vaccine delivery methods. For example, the use of microneedle patches and oral vaccines is gaining popularity due to their ease of administration and improved patient compliance. Despite these positive trends, challenges persist, including the lack of comprehensive vaccine coverage in some health plans and the ongoing impact of the COVID-19 pandemic on travel vaccination services. Nonetheless, the market's potential for growth remains strong, with opportunities for collaboration between stakeholders, including pharmaceutical companies, travel agencies, and healthcare providers.

What will be the Size of the Travel Vaccines Market during the forecast period?

Explore market size, adoption trends, and growth potential for travel vaccines market Request Free Sample

Travel vaccines represent a significant segment within the healthcare industry, with current market participation exceeding 20%. This figure underscores the importance of travel vaccines in safeguarding the health of globally mobile populations. Looking ahead, market expansion is anticipated to surpass 15% annually, driven by increasing awareness of disease prevention and the continuous development of innovative vaccine formulations. The market demonstrates a dynamic equilibrium between vaccine efficacy and patient compliance. For instance, in 2020, vaccine recommendations for hepatitis A and typhoid fever reached 90% and 70%, respectively, reflecting high levels of adherence. In contrast, compliance for yellow fever and rabies vaccines stood at 60% and 40%, respectively.
This disparity underscores the importance of effective vaccine education and public health initiatives to boost compliance rates and ultimately improve disease prevention. Moreover, advancements in vaccine manufacturing, cold chain management, and adjuvant systems have led to increased vaccine availability and efficacy. For example, cellular immunity responses to certain vaccines have shown promising results, leading to enhanced protection against various diseases. These advancements not only contribute to the market's growth but also improve overall traveler health and safety.

How is this Travel Vaccines Industry segmented?

The travel vaccines industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD million' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Disease Type

  Influenza
  Diptheria
  Hepatitis
  Typhoid and others


End-user

  Adult vaccines
  Pediatric vaccines


Type

  Outbound
  Inbound


Geography

  North America

    US
    Canada


  Europe

    France
    Germany
    Italy
    UK


  APAC

    China
    India
    Japan


  South America

    Brazil


  Rest of World (ROW)

By Disease Type Insights

The influenza segment is estimated to witness significant growth during the forecast period.

The market, specifically for influenza, is experiencing substantial expansion due to several factors. The resurgence of leisure and corporate travel to pre-pandemic levels and the increasing health awareness among travelers are primary drivers. Influenza vaccines are easily accessible, as they are widely available at pharmacies, healthcare facilities, and workplaces, making administration convenient for travelers. Moreover, disease surveilla

The Travel Vaccines Market Report Segments the Industry Into by Type (Cholera, Diptheria Pertussis Tetanus (DPT), Encephalitis, Hepatitis A, Meningococcal, Rabies, Typhoid, Yellow Fever, Other Types), by Travel Type (Domestic, Outbound), by Vaccination Center (Hospitals, Travel Clinics, Other Vaccination Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).

In Latin America Travel Vaccine Market is projected to grow from USD 4.6 billion in 2025 to USD 8.9 billion by 2031, at a CAGR of 11.2%

The global travel vaccines market was valued at USD 4 billion in 2023 and is projected to reach USD 8.1 billion by 2032, registering a CAGR of 9.5% during the forecast period (2024-2032).
Report Scope:

The global travel vaccines market size is projected to increase from USD 4.91 billion in 2025 to USD 12.62 billion by 2035, with CAGR growth above 9.9%. Major industry participants include Sanofi, Pfizer, GSK, Merck, Bavarian Nordic, driving growth and innovation in the market.

The global yellow fever vaccination market is projected to be a substantial market, valued at $132.7 million in 2025 and exhibiting a Compound Annual Growth Rate (CAGR) of 4.0% from 2025 to 2033. This growth is driven by several factors. Increased international travel and tourism contribute significantly, as many countries require proof of yellow fever vaccination for entry. Furthermore, ongoing efforts by organizations like UNICEF to bolster routine immunization programs in endemic regions are crucial for market expansion. The rising awareness of yellow fever's potential for outbreaks and the associated public health risks are also propelling demand for vaccination. While challenges exist, such as vaccine hesitancy in some populations and logistical hurdles in delivering vaccines to remote areas, the overall market outlook remains positive due to consistent public health initiatives and the inherent need for protection against this potentially lethal disease. The market is segmented by type (routine immunization, travelers, other) and application (self-procurement, UNICEF, other), reflecting the diverse avenues through which vaccines reach their intended recipients. Key players in the market include established pharmaceutical companies with expertise in vaccine production and distribution, ensuring a competitive landscape that drives innovation and accessibility. The market's geographic distribution is expected to reflect the prevalence of yellow fever and vaccination programs. Regions like Africa and South America, historically more prone to yellow fever outbreaks, are likely to dominate the market share, although substantial demand exists in regions with high international travel volume. The continued investment in research and development for improved yellow fever vaccines, such as those with extended shelf-life or enhanced efficacy, is a major factor contributing to market growth. The market's future hinges on effective public health strategies, successful vaccination campaigns, and sustained investment in vaccine production and distribution infrastructure. Growth may be influenced by factors including the efficacy of future vaccines, the emergence of new variants, and the impact of global health initiatives.

Yellow Fever Vaccines Market Outlook

According to our latest research, the global yellow fever vaccines market size reached USD 620 million in 2024, driven by persistent immunization efforts and heightened awareness in endemic and travel-prone regions. The market is projected to grow at a CAGR of 5.7% from 2025 to 2033, reaching approximately USD 1.01 billion by 2033. This robust growth is underpinned by increased international travel, government initiatives for mass vaccination, and rising outbreaks in endemic areas, all of which are fueling demand for yellow fever vaccines globally.

A key growth factor for the yellow fever vaccines market is the rising incidence of yellow fever outbreaks, particularly in sub-Saharan Africa and parts of Latin America. The World Health Organization (WHO) and other international health bodies have reported recurring epidemics, prompting governments to intensify vaccination campaigns and improve disease surveillance. These outbreaks not only heighten the urgency for immunization in endemic regions but also drive demand among travelers and expatriates. The growing recognition of yellow fever as a significant public health threat has led to increased funding and support for vaccine procurement and distribution, ensuring a consistent market demand.

Another crucial driver is the expanding global travel and tourism sector, which has heightened the risk of yellow fever transmission across borders. Many countries now mandate proof of yellow fever vaccination as an entry requirement, especially for travelers coming from or passing through endemic zones. This regulatory landscape has led to a surge in vaccine uptake among international travelers, business professionals, and military personnel. Additionally, the rising awareness of travel-related health risks and the increasing availability of travel clinics have further contributed to the growing adoption of yellow fever vaccines. As global mobility continues to rebound post-pandemic, this trend is expected to sustain market growth.

Technological advancements in vaccine development and manufacturing processes are also playing a pivotal role in market expansion. Innovations such as recombinant vaccine technologies and improved cold chain logistics have enhanced vaccine efficacy, safety, and accessibility. These advancements have enabled manufacturers to scale up production, address supply shortages, and reach remote populations more effectively. Furthermore, strategic collaborations between public health agencies, vaccine manufacturers, and non-governmental organizations have facilitated large-scale immunization programs, particularly in resource-limited settings. Such coordinated efforts are crucial in achieving high vaccination coverage and curbing the spread of yellow fever.

From a regional perspective, Latin America and Africa remain the largest markets for yellow fever vaccines due to the high prevalence of the disease and ongoing vaccination campaigns. These regions benefit from strong government support, international funding, and robust healthcare infrastructure dedicated to immunization. North America and Europe, while not endemic, represent significant markets owing to stringent travel regulations and a growing population of travelers to affected regions. The Asia Pacific market is witnessing steady growth, driven by increased awareness, improved access to vaccines, and rising outbound tourism. Overall, regional dynamics are shaped by a combination of epidemiological factors, regulatory policies, and healthcare infrastructure development.

Vaccine Type Analysis

The yellow fever vaccines market by vaccine type is segmented into live attenuated vaccines, inactivated vaccines, and recombinant vaccines, with live attenuated vaccines currently dominating global sales. Live attenuated vaccines, such as the widely used 17D strain, have established themselves as the gold standard due to their proven efficacy and long-lasting immunity. These vaccines are preferred for mass immunization campaigns and are re

Yellow Fever Vaccine Market size was valued at USD 144.87 Million in 2024 and is projected to reach USD 218.64 Million by 2032, growing at a CAGR of 5.28% from 2026 to 2032.

Yellow Fever Vaccine Market: Definition/ Overview The yellow fever vaccine is a live, attenuated virus vaccine used to prevent yellow fever, a dangerous disease spread mostly by mosquitos in Africa and South America. When given as a single subcutaneous dose, it often gives lifelong protection, making it critical for anyone living in or going to endemic areas. The vaccine is also necessary for entry into certain countries, demonstrating its importance in international travel health rules. The yellow fever vaccine has applications beyond individual protection; it is critical in outbreak control and is recommended for routine immunization in at-risk populations, considerably contributing to worldwide public health initiatives.

Combination Vaccine Market Outlook

The global combination vaccine market is poised to experience significant growth, with a market size valued at approximately USD 8.5 billion in 2023 and projected to reach USD 14.2 billion by 2032, driven by a compound annual growth rate (CAGR) of 5.5%. This steady growth is fueled by several factors, including the rising awareness of immunization's critical role in public health, the increasing prevalence of infectious diseases, and the continued support from government programs and non-governmental organizations dedicated to enhancing vaccination coverage worldwide.

The increasing prevalence of infectious diseases remains a primary driver propelling the growth of the combination vaccine market. As global travel and urbanization continue to rise, the risk of infectious diseases spreading across regions has heightened the demand for effective immunization strategies. Combination vaccines, which offer protection against multiple diseases with a single administration, are gaining traction due to their convenience and efficiency. Moreover, the growing awareness among healthcare professionals and the general public about the importance of vaccination in preventing disease outbreaks and reducing healthcare costs is acting as a catalyst for market expansion.

Technological advancements and continuous research and development activities are significantly enhancing the growth prospects of the combination vaccine market. Biopharmaceutical companies are investing heavily in the development of innovative vaccines that offer broader protection and fewer side effects. Advances in vaccine technology, such as the use of recombinant DNA technology and conjugate vaccines, have greatly improved the efficacy and safety of combination vaccines. These technological strides not only increase the effectiveness of vaccines but also expand the range of diseases that can be targeted, thus broadening the market's potential scope and application.

The active involvement of governments and international health organizations in vaccination initiatives is another critical factor driving the combination vaccine market. Governments worldwide are implementing programs to ensure widespread vaccination coverage, particularly for children and vulnerable populations. Subsidies, free vaccine programs, and public awareness campaigns are part of these initiatives, which aim to eliminate vaccine-preventable diseases. International health bodies such as the World Health Organization (WHO) and UNICEF are also playing a crucial role by providing technical and financial support to improve immunization infrastructure and accessibility, particularly in low and middle-income countries.

Regionally, North America is expected to continue leading the combination vaccine market, driven by high healthcare expenditure, robust healthcare infrastructure, and substantial investments in research and development. Meanwhile, Asia Pacific is anticipated to witness the fastest growth during the forecast period, fueled by rising healthcare awareness, improving economic conditions, and government-supported vaccination programs. As countries in Latin America, Europe, and the Middle East & Africa bolster their healthcare systems and prioritize immunization efforts, the combination vaccine market is likely to see a widespread increase in demand across these regions as well.

Vaccine Type Analysis

The vaccine type segment is broadly categorized into pediatric combination vaccines and adult combination vaccines, each serving distinct demographic needs. Pediatric combination vaccines are designed to protect infants and children from a variety of infectious diseases through a single inoculation schedule. The demand for these vaccines is particularly high due to the universal emphasis on childhood immunization, driven by the criticality of developing immunity during the formative years. Governments and health organizations continue to advocate for pediatric vaccination, fuelling the proliferation of innovative combination vaccines targeting diseases like diphtheria, tetanus, pertussis, and more.

Adult combination vaccines represent a growing segment, reflecting the increasing recognition of the need for vaccinations beyond childhood. With the aging global population and the resurgence of diseases traditionally considered pediatric, such as measles and mumps, there is a heightened demand for immunization strategies catering to adults. The

Yellow Fever Therapeutics Market Outlook

According to our latest research, the global yellow fever therapeutics market size reached USD 1.45 billion in 2024, driven by increasing vaccination campaigns and rising awareness in endemic regions. The market is expected to grow at a robust CAGR of 7.8% from 2025 to 2033, reaching an estimated USD 2.92 billion by 2033. Key growth factors include expanded immunization coverage, advancements in antiviral drug development, and increased government initiatives for disease control. The market is witnessing a surge in both preventive and therapeutic interventions, reflecting a strong commitment to reducing yellow fever incidence and mortality worldwide.

One of the primary drivers of the yellow fever therapeutics market is the intensification of global vaccination efforts. Governments and international health organizations have prioritized yellow fever immunization, especially in endemic areas of Africa and South America, where outbreaks continue to pose significant public health threats. The World Health Organization’s Eliminate Yellow Fever Epidemics (EYE) strategy has accelerated vaccine deployment, leading to higher coverage rates and a corresponding reduction in disease transmission. Increased funding from global health agencies has also facilitated the procurement and distribution of vaccines, making them more accessible even in remote regions. This comprehensive approach to vaccination not only curbs the spread of yellow fever but also bolsters market demand for both existing and next-generation vaccines.

Another significant growth factor is the advancement in antiviral drug research and development. While vaccination remains the cornerstone of yellow fever prevention, the need for effective therapeutics for those already infected is driving innovation in antiviral drug discovery. Pharmaceutical companies and research institutions are actively exploring novel compounds and combination therapies to address the unmet medical needs of severe yellow fever cases. The development of broad-spectrum antivirals and immunoglobulin therapies is particularly promising, as these options can potentially reduce morbidity and mortality in high-risk patient populations. The integration of new technologies, such as genomics and high-throughput screening, is accelerating the identification of promising therapeutic candidates, further stimulating market growth.

The increasing incidence of yellow fever outbreaks in non-endemic regions due to global travel and urbanization is also fueling market expansion. International travel has heightened the risk of yellow fever spread beyond traditional hotspots, prompting health authorities in North America, Europe, and Asia Pacific to strengthen surveillance and preparedness measures. This has led to heightened demand for yellow fever vaccines and therapeutics in travel clinics, hospitals, and pharmacies catering to international travelers. Additionally, urbanization in endemic regions has created new challenges for vector control, necessitating a multifaceted approach that combines vaccination, drug therapy, and public health education. The convergence of these factors is expected to sustain market growth throughout the forecast period.

From a regional perspective, the yellow fever therapeutics market exhibits strong growth potential across both developed and developing regions. Africa and Latin America remain the largest markets due to the high disease burden, but North America and Europe are witnessing rising demand for travel-related immunization and preparedness. Asia Pacific, while not traditionally endemic, is experiencing increased vigilance and investment in yellow fever prevention due to expanding international travel and trade. The Middle East and Africa region, in particular, is projected to show the fastest growth, with a CAGR exceeding 8.2%, as governments ramp up immunization campaigns and strengthen healthcare infrastructure. Overall, the market’s regional dynamics reflect a global commitment to yellow fever eradication and preparedness.

Drug Class Analysis

The drug class segment of the yellow fever therapeutics market is primarily categorized into vaccines, antiviral drugs, immunoglobulins, and others. Vaccines dominate this segment, accounting for the largest share of market revenue in 2024. The live attenuated yellow fever vaccine, which has been in use for decades, remains the gold standard for prevention and is recommen

According to Cognitive Market Research, the global Typhoid Vaccine market size is USD 361.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 13.0% from 2024 to 2031. North America held the major market share for more than 40% of the global revenue with a market size of USD 144.48 million in 2024 and will grow at a compound annual growth rate (CAGR) of 11.2% from 2024 to 2031. Europe accounted for a market share of over 30% of the global revenue with a market size of USD 108.36 million. Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 83.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 15.0% from 2024 to 2031. Latin America had a market share for more than 5% of the global revenue with a market size of USD 18.06 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.4% from 2024 to 2031. Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 7.22 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.7% from 2024 to 2031. The Live Attenuated Vaccine held the highest Typhoid Vaccine market revenue share in 2024. Market Dynamics of Typhoid Vaccine Market Key Drivers for Typhoid Vaccine Market High Burden of Typhoid Fever to Increase the Demand Globally Typhoid fever persists as a pressing public health difficulty in numerous growing areas, appreciably South Asia and Sub-Saharan Africa. Its extensive disease burden necessitates ongoing efforts to put into effect powerful preventive techniques, fundamental among them being vaccination. With endemic transmission and common outbreaks, these regions face a steady demand for strong immunization applications to shrink the spread of the disorder. Enhancing access to vaccines, coupled with complete public fitness interventions, is critical in mitigating the impact of typhoid fever and assuaging the weight it locations on affected groups. Increased Travel and Tourism to Propel Market Growth The surge in worldwide tour and tourism amplifies the danger of typhoid fever exposure, specifically for individuals touring endemic areas. This trend heightens the need for typhoid vaccination among vacationers, as they face a multiplied likelihood of encountering the pathogen for the duration of their journeys. The imperative accordingly propels the demand for such vaccinations to protect tourists from the potentially debilitating effects of the ailment. By prioritizing immunization as a preventive measure, tourists can mitigate the danger of contracting typhoid fever and contribute to the containment of its spread throughout borders. This underscores the critical function of vaccination packages in safeguarding the fitness and well-being of individuals engaged in global journeys and tourism. Restraint Factor for the Typhoid Vaccine Market Limited Vaccine Availability to Limit the Sales In certain regions, regardless of escalating calls for, get right of entry to to typhoid vaccines remains restrained due to different factors together with logistical hurdles, inadequacies in bloodless chain infrastructure, or periodic vaccine stockouts. These demanding situations obstruct the consistent availability of vaccines, thereby hindering efforts to immunize populations at chance efficaciously. Consequently, individuals living in or visiting to those regions may additionally come upon problems in gaining access to critical preventive measures towards typhoid fever. Addressing those obstacles necessitates comprehensive strategies encompassing enhancements in vaccine distribution networks, bolstering bloodless chain infrastructure, and enhancing stock management structures. By surmounting those barriers, stakeholders can ensure equitable get admission to to typhoid vaccines, thereby fortifying worldwide efforts to fight the load of this infectious sickness. Impact of Covid-19 on the Typhoid Vaccine Market The COVID-19 pandemic has had an excellent effect on the typhoid vaccine market, disrupting supply chains, distribution networks, and vaccination campaigns. Redirected assets, logistical challenges, and prioritization of COVID-19 reaction efforts have impeded the availability and admission of typhoid vaccines in many regions. Additionally, lockdown measures, tour regulations, and decreased healthcare usage have confined opportunities for vaccination, affecting each habitual immunization package a...

Meningococcal Infections Vaccine Market Outlook

The meningococcal infections vaccine market size is projected to expand significantly from its valuation of approximately $3.4 billion in 2023 to an estimated $5.8 billion by 2032, achieving a compound annual growth rate (CAGR) of 6.3% over the forecast period. This growth is primarily driven by increased awareness of the severe health threats posed by meningococcal infections, alongside advancements in vaccine technology and integration of immunization programs into healthcare policies globally. With the rise in travel and urbanization, the need for effective vaccination against potential outbreaks has become more pronounced, further bolstering the market growth.

The rise in global travel and urbanization is a significant growth driver for the meningococcal infections vaccine market. As people travel more frequently, the potential for meningococcal disease to spread increases, necessitating robust vaccination programs. Urbanization contributes to higher population densities, which can facilitate the rapid transmission of infectious diseases, including meningococcal infections. These factors have led to increased governmental and non-governmental efforts to promote vaccination as a preventive measure. The development of more effective vaccines, capable of addressing multiple strains of Neisseria meningitidis, is a testament to the advancements in the field, which fuel market growth. Furthermore, the integration of meningococcal vaccines into national immunization programs in many countries reflects a proactive approach towards disease prevention, significantly boosting market demand.

Technological advancements in vaccine development have also played a crucial role in the market's growth. Innovations such as conjugate vaccines and combination vaccines have enhanced the efficacy and safety of meningococcal vaccines, leading to wider acceptance and uptake. Conjugate vaccines, for instance, offer longer-lasting immunity and are effective across various age groups, making them a preferred choice in immunization schedules. The ongoing research into more comprehensive vaccines that offer protection against multiple serogroups simultaneously is likely to spur further growth by broadening the scope of preventive care and simplifying vaccination logistics. These scientific endeavors are supported by substantial investments from both public and private sectors, highlighting the prioritization of preventive healthcare measures in global health agendas.

Moreover, the increasing awareness of the morbidity and mortality associated with meningococcal infections is encouraging governments and health organizations to invest more in preventive healthcare measures, including vaccination programs. Educational campaigns and initiatives to improve public knowledge about meningococcal disease and the benefits of vaccination are proving effective in maximizing vaccine coverage. Additionally, the inclusion of meningococcal vaccines in routine immunization schedules for infants, children, and adolescents in several countries is indicative of a strong commitment to disease prevention, contributing significantly to the market's expansion. The focus on preventive healthcare is expected to continue as health systems strive to minimize the burden of infectious diseases.

Regionally, North America currently holds a significant share of the meningococcal infections vaccine market, owing to the presence of a robust healthcare infrastructure, high awareness levels, and supportive governmental policies. However, the Asia Pacific region is anticipated to witness the fastest growth during the forecast period, driven by increasing health expenditure, rising awareness, and expanding immunization coverage. The growing population and urbanization in Asia Pacific also contribute to this trend. Europe maintains a steady growth trajectory due to strong public health systems and established immunization programs. Meanwhile, regions such as Latin America and the Middle East & Africa are gradually increasing their vaccination efforts, propelled by international collaborations and funding to enhance healthcare access and infrastructure.

Vaccine Type Analysis

The meningococcal infections vaccine market is segmented into polysaccharide vaccines, conjugate vaccines, and combination vaccines, each serving distinct roles in the prevention of this infectious disease. Polysaccharide vaccines, which were among the first developed, have been instrumental in providing immunity against meningococcal infections. They work by using long chains of sugar molecules that mimic the coating of the bacteria to sti

The Travel Vaccines Market Report Segments the Industry Into by Type (Cholera, Diptheria Pertussis Tetanus (DPT), Encephalitis, Hepatitis A, Meningococcal, Rabies, Typhoid, Yellow Fever, Other Types), by Travel Type (Domestic, Outbound), by Vaccination Center (Hospitals, Travel Clinics, Other Vaccination Centers), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America).